Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America Anticipated Year-End 2026 Presented Results Reinforcing Bemnifosbuvir/Ruzasvir as a Potential Best-in-Class Regimen for the Treatment of HCV at the 2025 EASL Congress and The Liver Meeting® 2025, the Annual Meeting of AASLD Physician KOLs Underscored the Need for a New Optimized HCV Regimen to Address Treatment Paradigm Shifts, Including Test-and-Treat Model of Care Expanded Antiviral Pipeline with New Hepatitis E Virus (HEV) Program; Lead Product Candidate AT-587 Expected to Enter Clinic Mid-2026 Company Holding Conference Call Today at 4:30 PM ET BOSTON, March 05, 2026 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc....

Company Advances Strategic Transition, Expands IntentKey®, and Provides 2026 Outlook Management to host conference call at 4:15 PM ET, Thursday, March 5, 2026 LITTLE ROCK, Ark., March 05, 2026 (GLOBE NEWSWIRE) — Inuvo, Inc. (NYSE American: INUV), a leader in artificial intelligence-driven advertising technology, today announced financial results for the fourth quarter and full year ended December 31, 2025. Key Developments in 2025Strategic Platform Reset: Reduced participation in certain lower-quality Platform activity in order to drive more sustainable, compliant revenue streams, strengthen margins and increase long-term business stability. Operating Discipline: Streamlined operations and aligned spending with core AI and Platform strategy. IntentKey Product Expansion: Expanded IntentKey AI capabilities by introducing IntentPath,...

GLP toxicology studies ongoing for CMP-002, with initiation of global Phase 1/2 clinical trial in SYNGAP1 patients expected as early as 2H 2026 Entered strategic collaboration with GSK to advance RNA-based therapeutic discoveries, received $17.5 million upfront and eligible for milestone-based payments in addition to tiered royalties Completed private placement with upfront gross proceeds of $50 million, with potential for up to an additional $50 million of gross proceeds, as well as underwritten offering of common stock of $30 million in gross proceeds, extending cash runway into 2028 CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) — CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression...

Revenue up 58% in Fourth Quarter, 53% for Year; Member Growth of 55% for YearAchieves Positive Net Income in Fourth Quarter; Significantly Narrows Net Loss for Full Year Delivers Positive Adjusted EBITDA for Full Year SAN FRANCISCO, March 05, 2026 (GLOBE NEWSWIRE) — Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the fourth quarter and full year ended December 31, 2025. 2025 Fourth Quarter and Full-Year HighlightsHighlights are for the fourth quarter and full year 2025, except where otherwise noted. Total members886,000 at year end, up 55% year over yearRevenue$76 million in the fourth quarter, up 58% year over year $260 million for the full year, up 53% compared with 2024GLP-1 LeadershipOmada has now supported more than 150,000 members on GLP-1s,...

LIMASSOL, Cyprus, March 05, 2026 (GLOBE NEWSWIRE) — GDEV Inc. (NASDAQ: GDEV), an international gaming and entertainment company (“GDEV” or the “Company”) released its preliminary, unaudited financial and operational results for the fourth quarter and twelve months ended December 31, 2025. Fourth quarter 2025 financial highlights:Revenue of $90 million decreased by 8% year-over-year. Selling and marketing expenses of $35 million decreased by 25% year-over-year. Profit for the period, net of tax, of $14 million in Q4 2025 increased vs. $2 million in Q4 2024. Adjusted EBITDA1 of $15 million in Q4 2025 increased vs. $9 million in Q4 2024.Fourth quarter and twelve months 2025 financial performance in comparisonUS$ million Q4 2025 Q4 2024 Change (%) 12M 2025 12M 2024 Change (%)Revenue 90 98 (8%) 404 421 (4%)Platform commissions (18) (21) (13%) (85) (91) (7%)Game...

Initiates 2026 guidance, anticipating another record year BELGRADE, Mont., March 05, 2026 (GLOBE NEWSWIRE) — Bridger Aerospace Group Holdings, Inc. (“Bridger”, “the Company” or “Bridger Aerospace”), (NASDAQ: BAER, BAERW), one of the nation’s largest aerial firefighting companies, today reported financial results for the fourth quarter and year ended December 31, 2025, including positive net income for the full year. Highlights:Revenue for 2025 grew 25% to $122.8 million, surpassing the company’s increased guidance range Positive Net Income for 2025 was $4.1 million, with adjusted EBITDA increasing 21% from 2024 to $45.3 million Completed $331.5 million financing package, including debt refinancing and a $100.0 million delayed draw facility, to bolster financial flexibility and fund strategic fleet expansion amid rising demand...

Thursday, March 05, 2026 PRESS RELEASE: Annual Accounts 2025Good resilience of Savencia in a difficult dairy context   Approval of the merger between Savencia Fromage & Dairy and Savencia Gourmet’s Chocolate activities to accelerate the development of Premium Foodservice   Completion of the acquisition of Quata in BrazilKey figures in €M   31/12/25   % CA   31/12/24   % CA   Changes in %Total Structure Change & IAS 29 Growth OrganicSales 6 957   7 140   -2.6 0.2 -4.3 1.6– Cheese products 4 017 57.7 4 055 56.8 -1.0 0.0 -0.9 0.0– Other dairy products 3 184 45.8 3 328 46.6 -4.3 0.3 -8.4 3.7– Unallocated -245 -3.5 -244 -3.4        Current Operating Profit 210.5 3.0 232.3 3.3 The audit procedures have been carried out and the audit report relating to certification is currently...

Date: 5 March 2026 Release: After closing of Euronext Please open the following link to read the full report including annexes:AttachmentFULL PRESS RELEASE

SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the fourth quarter and full year 2025. “Our team has made tremendous progress recently in the global Phase 2 B-SUPREME study of pevifoscorvir sodium,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “With the completion of the planned enrollment in the HBeAg- cohort, we are continuing to enroll participants in the HBeAg+ cohort and look forward to the interim analyses in the first and second half of 2026. Additionally, the Phase 2 B-SUPREME study may demonstrate...

WILMINGTON, Del., March 05, 2026 (GLOBE NEWSWIRE) — Acorn Energy, Inc. (Nasdaq: ACFN), provider of remote monitoring and control solutions for critical infrastructure assets, announced results for its fourth quarter (Q4’25) and full-year ended December 31, 2025. Acorn will hold an investor call today at 11 a.m. ET (details below).Summary Financial Results ($ in thousands)   Q4’25     Q4’24   Change     2025     2024   ChangeMonitoring revenue $ 1,411   $ 1,203     +17.3 %   $ 5,560   $ 4,553     +22.1 %Hardware revenue $ 966   $ 2,326     -58.5 %   $ 5,918   $ 6,433     -8.0 %Total revenue(1) $ 2,377   $ 3,529     -32.6 %   $ 11,478   $ 10,986     +4.5 %Gross margin   80.1 %   72.4 %   +770 bps     76.8 %   72.8 %   +400 bpsNet income to stockholders (2) $ 1,074   $ 5,233     -79.5 %   $ 2,510   $ 6,294     -60.1 %Diluted...